<DOC>
	<DOC>NCT00088062</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.</brief_summary>
	<brief_title>STA-5326 in Crohn's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Patients 1865 years old Crohn's Disease for 6 months CDAI scores between 220450 +/ 5ASA, stable dose for &gt; 2 weeks +/ Corticosteroids, less than or equal to 40 mg per day with a stable dose for 2 weeks +/ Infliximab with no treatment within 4 weeks +/ 6Mercaptopurine, with a stable dose for 8 weeks +/ Antibiotics, with a stable dose for 2 weeks Patients who have had methotrexate, cyclosporine, or other experimental drug within 3 months of screening Pregnancy, breast feeding History of total proctocolectomy with stoma. Previous ileocolectomy would not be a contraindication to the study Bowel obstruction Surgical bowel resection within 90 days Total parenteral nutrition (TPN), CYA, tacrolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>Crohn's Disease</keyword>
</DOC>